Biotech News

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB Biotherapeutics (SABS)SAB Biotherapeutics2026-04-22 11:00 ESTClinical readout

All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-142 showed improved glycemic control MIAMI, April 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics,

Open original release

Related news

SABSSAB Biotherapeutics2026-03-10 11:31 EST

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

SABSSAB Biotherapeutics2026-04-15 12:00 EST

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

CLDXCelldex Therapeutics2026-06-14 09:15 EST

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

NRIXNurix Therapeutics2026-05-14 20:06 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

BMYBMYBristol-Myers Squibb Company2026-03-29 15:45 EST

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

MLTXMoonLake Immunotherapeutics2026-03-28 19:00 EST

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

BNTXBioNTech2026-05-30 18:15 EST

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

REGNRegeneron Pharmaceuticals2026-05-05 11:00 EST

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

View all latest news

SAB Biotherapeutics

SAB Biotherapeutics is a biopharmaceutical company focused on human polyclonal antibodies and immune therapy. Its platform aims to create broad immune responses for infectious and inflammatory diseases.

Recent company news

SABSSAB Biotherapeutics2026-07-07 12:00 EST

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SABSSAB Biotherapeutics2026-05-12 11:30 EST

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SABSSAB Biotherapeutics2026-05-05 12:30 EST

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-04-22 11:00 EST

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

Stock data

Close: 3.44 USD
Market cap: 266.1M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States